Advertisement
Advertisement
U.S. markets open in 5 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
61.69-1.38 (-2.19%)
At close: 04:00PM EDT
61.80 +0.11 (+0.18%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close63.07
Open63.16
Bid0.00 x 3000
Ask0.00 x 1000
Day's Range61.61 - 63.58
52 Week Range57.17 - 74.12
Volume8,794,843
Avg. Volume6,819,650
Market Cap77.32B
Beta (5Y Monthly)0.33
PE Ratio (TTM)18.87
EPS (TTM)3.27
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & Yield2.92 (4.73%)
Ex-Dividend DateSep 14, 2022
1y Target Est71.07
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
32% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GILD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gilead Sciences, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
Advertisement
Advertisement